Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257486 · ClinicalTrials.gov registry record
Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
A clinical trial, sponsored by Xoft.
- Completed
- Registry status
- 183
- Enrollment target
NCT05257486 is a clinical trial that has completed, run by Xoft. The registered enrollment target is 183 participants.
The verdict
NCT05257486 has completed, sponsored by Xoft.
- COMPLETED
- Registry status
- 183 participants
- Enrollment target
Study Summary
The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.
Interventions
- DEVICE Xoft eBx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-10-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257486
The ClinicalTrials.gov registry entry for NCT05257486 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoft, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xoft eBx is the first listed.
NCT05257486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05257486 about?
NCT05257486 is a clinical study titled "Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx". The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.
What is the current status of trial NCT05257486?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2022-03-09. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT05257486?
The interventions under investigation include: Xoft eBx (DEVICE).
Who is sponsoring clinical trial NCT05257486?
This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.